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Reply to the Editor:
My coauthors and I thank Drs Kourliouros,
Roberts, and Jahangiri for their interest in
our recent study.1 We do not disagree with
their suggestion that different statins may
exhibit varying degrees of pleiotropic
effects (eg, anti-inflammatory effects), and
thus believe that their hypothesis that statins
may have differential abilities to prevent
postcardiothoracic surgery (CTS) atrial fi-
brillation is not unreasonable. It is, however,
important to note that the intent of our
nested cohort study was to assess whether
statins as a class are associated with reduc-
tions in post-CTS atrial fibrillation when
used in patients who already have a high
background use of b-blockers (84%) and
appreciable use of prophylactic amiodarone
(44%), rather than to evaluate individual
statins or a dose-response relationship.1
Our primary analysis was worthwhile,
because a large proportion of patients in
ARMYDA-3—the only randomized con-
trolled trial designed to assess the effect of
a statin (atorvastatin at 40 mg/d) on post-
CTS atrial fibrillation as a primary end
point—did not receive b-blockers (arguably
the criterion standard preventative strategy),
and virtually none received prophylactic
amiodarone.2 This treatment pattern likely
explains the high incidence of post-CTS
atrial fibrillation (57%) seen in the AR-
MYDA-3 control group.
Despite the criticism by Kourliouros,
Roberts, and Jahangiri of our dose-response
analysis, we believe that it provides valuable
data to support the claim of a dose-response
effect of statins on post-CTS atrial fibrilla-
tion. We would have liked to evaluate
different statins and doses independently;
however, the relatively small number of
patients receiving a statin and the heteroge-
neous uses of different statins and doses
by patients enrolled in the cohort would
have resulted in an underpowered analysis.1
That being said, we applaud the work of
Kourliouros, Roberts, and Jahangiri in con-
ducting an additional analysis to further the
research in this area.3 Ultimately, as Kour-
liouros, Roberts, and Jahangiri suggest, all
nonrandomized studies likely suffer from
some degree of bias or confounding, which
is why a randomized, controlled trial will be
needed to determine definitively whether
different statins exhibit different abilities to
prevent post-CTS atrial fibrillation and
whether dose-response relationships do, in
fact, exist.
Craig Ian Coleman, PharmD
University of Connecticut School of Pharmacy
Storrs, Conn
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Box lesion or not—Still
unsettled question
To the Editor:
I read with interest the article by Voeller and
associates1 in the April 2008 issue of the
Journal. This is a single center study look-
ing at occurrences of atrial arrhythmias on
follow-up in patients who had the Cox
maze IV procedure with and without box le-
sions. Although the authors have acknowl-
edged several limitations, I would like to
point out another important limitation.
Over 60% of the patients had concomitant
procedures, and a significant proportion of
them had valve operations, which is a signif-
icant confounder for occurrence of postop-
erative atrial arrhythmias. Analysis of the
lone Cox maze IV group would probably of-
fer better insight into the benefit of the box
lesion. However, the numbers seem to be
so small that there may not be adequate
power for this analysis. I will look forward
to any follow-up data in the future from
the authors.
Uma N. Srivatsa, MD
Internal Medicine/Cardiology
University of California—Davis
Sacramento, CA 95670
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Letters to the EditorAortic valve replacement
dilemma: mechanical or
biological prosthesis?
To the Editor:
The selection of the appropriate prosthesis
for aortic valve replacement (AVR) is still
open to debate in the case of patients in
the sixth and seventh decades of life.
Recently Brown and colleagues,1 from
Mayo Clinic, reported in the Journal on
an interesting retrospective study about
this topic. By means of patient matching
according to clinical features, they ob-
served in their population a survival advan-
tage after aortic valve replacement with
a mechanical prosthesis relative to a bio-
prosthesis. Brown and colleagues1 stated
that the study was subject to selection
bias and noted that despite case matching
and statistical analysis, surgical bias cannot
be eliminated. Also, in our opinion, it is
virtually impossible to avoid at all biases
and confounding factors in clinical studies.
Nevertheless, the recording of aortic valve
replacement as associated or not with coro-
nary artery bypass grafting simply as a bi-
nary variable could be quite misleading in
drawing conclusions from data analysis.
In fact, age being equal, surgeons could
elect to implant a bioprosthesis rather
than a mechanical valve in patients affected
by more severe coronary artery disease.
Both the extent—isolated single-vessel dis-
ease versus triple-vessel disease—and ther Surgery c Volume 136, Number 4 1101
tion can distribute unmeasured covariates
evenly between groups.
A question was raised regarding the
extent of coronary artery disease. We
used coronary artery bypass grafting as
a surrogate for coronary artery disease,
and the mean numbers of grafts per patient
were 1.0 6 1.3 in the mechanical aortic
valve group and 1.0 6 1.2 in the biopros-
thetic aortic valve group (P 5 .86). We
performed an analysis of survival of pa-
tients undergoing aortic valve replacement
with and without coronary artery bypass
grafting (Figure 1). The survival benefit
we observed with a mechanical aortic
valve appears, however, to be independent
of the presence of coronary artery disease
in our multivariate model, as shown in
Table 5 of our original article.1
Our finding of a survival benefit in the
mechanical aortic valve group was surpris-
ing, and we have hypothesized that one
possible explanation would be patient–pros-
thesis mismatch. We do not have the effec-
tive orifice area data available for this
study group. We have, however, included
information regarding body surface area
and body mass index, size of prosthesis,
concern is with the growing trend toward
placing bioprosthetic aortic valves in youn-
ger patients. All observational (retrospective
or prospective) studies are unable to elimi-
nate the potential impact of patient selection
bias; however, this investigation adds equi-
poise.
Morgan Brown, MD
Hartzell Schaff, MD
Division of Cardiovascular Surgery, Mayo
Clinic, Rochester, MN
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Importance of stabilization of
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Figure 1. Survivals in mechanical aortic valve (Mech V) and bioprosthetic aortic valve
(BPV) groups according to presence or absence of coronary artery disease, as indicated
by coronary artery bypass grafting (CABG).
Letters to the Editorseverity—proximal isolated stenoses ver-
sus multiple stenoses with distal vessel in-
volvement—are features of coronary artery
disease that strongly influence surgical
strategy, complexity of the operation, and
prognosis. Moreover, the quality of coro-
nary vessels and graft availability and qual-
ity determine the completeness of the
revascularization and its durability. With
the matching method adopted by Brown
and colleagues,1 these data are lost to the
analysis, making it impossible to evaluate
any effects on the higher perioperative
and long-term mortalities observed in the
bioprosthesis group. Higher mortality
could be related to an unfavorable preoper-
ative status. In that case, the surgeons who
performed the operations may have shown
good clinical judgment, implanting bio-
prostheses in patients with poor prognosis.
Moreover, there are no data on prosthesis
sizes, effective orifice areas, and the inci-
dence of patient–prosthesis mismatch, all
of which could influence long-term results.
In conclusion, Brown and colleagues de-
serve commendation for the insights from
their interesting study. Nevertheless, ex-
treme caution should be exercised in sup-
porting or questioning existing clinical
guidelines in response to potentially biased
retrospective studies.
Aldo Cannata, MD
Claudio Francesco Russo, MD
Corrado Taglieri, MD
Angelo De Gasperis Department of Cardiac
Surgery Niguarda Ca` Granda Hospital
Milan, Italy
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Drs Cannata, Russo, and Taglieri com-
mented on our results and the possible
impact of selection bias, which is present
in all observational surgical series. We
matched patients and used multivariate anal-
yses, but it is impossible to determine
whether this has accounted for all possible
confounders.We agree that only randomiza-
and the incidence of aortic root enlargement
in each group (see Table 1 in our original ar-
ticle). In general, surgeons at our clinic
perform aortic root enlargement to accom-
modate a larger prostheses in any patient
who is at risk for patient–prosthesis mis-
match.2
We believe that current guidelines are
generally appropriate for mechanical or bio-
prosthetic valve selection. Our primary
the mitral annulus in mitral valve
repair
To the Editor:
We read with great interest the article of
Flameng and coauthors1 about their expe-
riences with mitral valve repair in Barlow
disease and fibroelastic deficiency. They
found that not using annuloplasty ring
in mitral valve repair is a risk factor for
recurrent mitral valve regurgitation. We
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